chartexchange

Climb Bio to Present New Data for Budoprutug in Immune Thrombocytopenia at the 68th American Society of Hematology Annual Meeting and Exposition

GlobeNewswire Inc. | Nov 4, 2026 9:00 AM EST

WELLESLEY HILLS, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that it will present new clinical data for budoprutug in immune thrombocytopenia (ITP) at the 68 th American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held in New Orleans, Louisiana from December 12-15, 2026.

Read original article